GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations
GSK has vastly expanded its market for cancer therapy Zejula — the crown jewel at the heart of its $5 billion acquisition of Tesaro — by winning FDA approval for the drug in a large subset of patients with ovarian cancer.
The approval comes for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who experienced a complete or partial response to first-line platinum-based chemotherapy — accounting for approximately 80% of all ovarian cancer patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.